Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill amends section 317K of the Public Health Service Act to reauthorize and expand federal support for State-based maternal mortality review committees, to require the Centers for Disease Control and Prevention (in consultation with HRSA) to disseminate best practices on preventing maternal mortality to hospitals, State professional societies, and perinatal quality collaboratives at least once per year, and to improve coordination with death certifiers including authority to amend cause-of-death information on death certificates as appropriate. It updates committee membership language to explicitly include obstetricians/gynecologists and other clinical specialties, clarifies coordination with death certifiers to improve death record quality, and redesignates subsections to add a new subsection on best practices.
Degree of federal involvement and oversight: liberals favor stronger federal guidance and equity targeting; conservatives want limits and more state control.
Relative to its intended legislative type, this bill is a clear statutory reauthorization and targeted expansion of an existing public-health program: it amends the Public Health Service Act, prescribes responsible agencies, mandates annual dissemination of best practices, and authorizes multiyear funding.
The bill amends section 317K of the Public Health Service Act to reauthorize and expand federal support for State-based maternal mortality review committees, to require the Centers for Disease Control and Prevention (in consultation with HRSA) to disseminate best practices on preventing maternal mortality to hospitals, State professional societies, and perinatal quality collaboratives at least once per year, and to improve coordination with death certifiers including authority to amend cause-of-death information on death certificates as appropriate.
It updates committee membership language to explicitly include obstetricians/gynecologists and other clinical specialties, clarifies coordination with death certifiers to improve death record quality, and redesignates subsections to add a new subsection on best practices.
The bill specifies funding of $100,000,000 for each fiscal year 2026 through 2030 (replacing the prior authorization level of $58,000,000 for fiscal years 2019–2023).
Based solely on the text, the bill is a modest, technical public‑health measure with bipartisan appeal potential and a clear administrative pathway (CDC/HRSA) to implementation. The main obstacles are fiscal — it authorizes a materially larger funding level that would require appropriations — and ordinary legislative process constraints (committee consideration, scheduling, and possible attachment to larger bills). Its non-ideological nature raises its chances compared with polarizing legislation, but passage is not guaranteed because authorization does not equal appropriation and procedural hurdles remain.
Relative to its intended legislative type, this bill is a clear statutory reauthorization and targeted expansion of an existing public-health program: it amends the Public Health Service Act, prescribes responsible agencies, mandates annual dissemination of best practices, and authorizes multiyear funding. The drafting integrates cleanly into existing law and specifies parties responsible for carrying out the new duties.
Degree of federal involvement and oversight: liberals favor stronger federal guidance and equity targeting; conservatives want limits and more state control.
These are examples from the analysis, not a ranked list of the most-affected groups.
Degree of federal involvement and oversight: liberals favor stronger federal guidance and equity targeting; conservatives want limits and more state control.
A mainstream progressive would likely view this bill positively as a practical, evidence-based step to reduce maternal deaths and improve data needed to target disparities.
They would appreciate the funding increase, the clearer inclusion of clinical specialists on review committees, the enhanced support for state review processes, and the annual dissemination of best practices by CDC/HRSA.
They may nonetheless feel the bill could be stronger on explicitly addressing racial and socioeconomic disparities and on ensuring funds reach community-based programs.
A pragmatic, moderate observer would view the bill as a reasonable, evidence-oriented public health measure with bipartisan appeal: it funds state review activities, improves data quality, and instructs federal agencies to disseminate best practices.
They would welcome clearer expectations about accountability, measurable outcomes, and oversight to ensure fiscal responsibility and avoid duplication with state programs.
They would likely want implementation details—reporting, performance metrics, and transparent allocation—before full endorsement.
A mainstream conservative would likely view the bill as a modest, largely noncontroversial public-health measure because it targets maternal mortality — a broadly sympathetic objective — but would express concerns about the increased federal spending, potential federal overreach into state and clinical decision-making, and added bureaucratic obligations.
They would want safeguards to preserve state authority, limit federal administrative expansion, and ensure the new funding is accountable and efficient.
If those concerns are addressed, many conservatives could be cautiously supportive, though some fiscal conservatives may prefer smaller appropriations or state-directed grants.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Based solely on the text, the bill is a modest, technical public‑health measure with bipartisan appeal potential and a clear administrative pathway (CDC/HRSA) to implementation. The main obstacles are fiscal — it authorizes a materially larger funding level that would require appropriations — and ordinary legislative process constraints (committee consideration, scheduling, and possible attachment to larger bills). Its non-ideological nature raises its chances compared with polarizing legislation, but passage is not guaranteed because authorization does not equal appropriation and procedural hurdles remain.
The bill has not accumulated any surfaced votes yet.
Degree of federal involvement and oversight: liberals favor stronger federal guidance and equity targeting; conservatives want limits and m…
Based solely on the text, the bill is a modest, technical public‑health measure with bipartisan appeal potential and a clear administrative…
Relative to its intended legislative type, this bill is a clear statutory reauthorization and targeted expansion of an existing public-health program: it amends the Public Health Service Act, prescribes responsible agen…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.